ORIC oricpharma.com: Enterprise Value to EBITDA Ratio

Corporate company logo of oricpharma.com (ORIC)

Investing in ORIC Pharmaceuticals (ORIC) involves a high dependency on the test results of a narrow portfolio and the risk of funding shortages. The EV/EBITDA ratio of this capital-intensive business reflects valuation dynamics, where 0.00 captures the current value of the indicator. ORIC Pharmaceuticals (ORIC) develops small molecules to combat tumor resistance, offering breakthrough treatments for severe forms of cancer that are currently undergoing clinical trials.

ORIC (ORIC Pharmaceuticals Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/10/2026

Comprehensive metric breakdowns and analytics for oricpharma.com (ORIC)

- stock price and consensus target price:
Stock Quotes ORIC Pharma|ORIC - Average Forecast Price
- company stock capitalization data:
Market Valuation ORIC Corp|ORIC - Value Adjusted for Debt and Cash
- business book valuation details:
Accounting Value per Share ORIC Pharmaceuticals|ORIC - Total Net Assets|Market Capitalization to Book Value Ratio oricpharma.com|ORIC - Company Total Assets
- debt and solvency information:
Debt to Equity ORIC Pharmaceuticals|ORIC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital ORIC Pharmaceuticals, Inc.|ORIC - Company Total Indebtedness|Debts to Book Capitalization ORIC Corp|ORIC - Long-Term Debt|Company Current Liabilities ORIC Pharmaceuticals|Quick Ratio oricpharma.com
- net income and valuation multiples indicators:
ORIC - Company Net Income|Projected Future Earnings ORIC Pharmaceuticals|ORIC - Price to Earnings Multiple|Projected Price to Earnings ORIC Pharmaceuticals|ORIC - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio ORIC Corp|ORIC - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) ORIC Pharmaceuticals|ORIC - Earnings per share for the trailing year|Quarterly EPS earnings growth oricpharma.com|ORIC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year ORIC Pharmaceuticals
Basic company analysis:ORIC Pharma ORIC
Original product of oricpharma.com

The EV/EBITDA multiple compares the total enterprise value, including debt, with operating profit before taxes and amortization to reveal the extent of asset overvaluation. For ORIC Pharmaceuticals (ORIC), whose R&D expenses and losses are already priced in, the current EV/EBITDA multiple serves as an indicator of critical overheating and the risk of a drawdown should there be delays in the clinical trials of target molecules.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|RLAY (Relay Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Nurix Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GLUE (Monte Rosa Therapeutics, Inc.)|Enterprise Value to EBITDA Multiple Cullinan Oncology|Immuneering Inc. - EV/EBITDA Multiple|Company Value to EBITDA C4 Therapeutics Corp|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple